Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aurinia Pharmaceuticals Inc AUPH

Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.


NDAQ:AUPH - Post by User

Bullboard Posts
Post by highshooteron Apr 08, 2017 2:42pm
251 Views
Post# 26096209

Am I lost never head of CellCept before.....Someone ????

Am I lost never head of CellCept before.....Someone ????

News from MOTLEY FOOL

In a mid-stage phase 2b study, adding voclosporin to CellCept not only improved patient response rates, but it also reduced patients reliance on steroids. The 48-week global study showed that the two-drug combination delivered a complete response rate of 49% at the 23.7 mg dose. That was far better than the 24% complete remission rate observed in the control group, which didn't receive voclosporin. 

Adding voclosporin to CellCept therapy also resulted in more patients achieving at least a partial response. In the two-drug combination, the partial response rate was 68% in the 23.7 mg dose arm. The rate in the control arm was just 48%.
Anybody knows about CellCept part of phase 3 ????

Bullboard Posts